The future of AAV vector-based therapies holds great promise if manufacturers can cope with the demand. While in-house manufacturing may be an option for some companies, partnering with a CDMO can be the best choice for others. Teaming up with a One-Stop-Shop CDMO can make it easier to achieve the project goals. There are many reasons for this.
The German Patent System has been a very patentee-friendly system, in particular for smaller patentees. Enforcement of patents has been relatively easy, affordable and fast.
Study start-up is a chaotic time. There are lots of moving parts. Lots of decisions to make and processes to establish. Lots of room for error. Mistakes can quickly derail a trial – and delays are endemic. That all represents a potential waste of time and resources – just at a moment when speed is of the essence. In many cases, the problem comes down to spreadsheets.
Africa produces less than 1% of the human vaccines it uses. To effectively respond in time of outbreaks and pandemics, Africa must expand its vaccine development and production capabilities to cater for its growing population. Successfully establishing such an industry at scale is a multifaceted endeavour to create an enabling environment. This article highlights key factors and considerations for establishing local vaccine manufacturing.
IP – In a recent decision (Royalty vs. DPMA; C-650/17), the European Court of Justice (ECJ) has shed some light on the conditions under which a supplementary protection certificate (SPC) may be granted. It has thus ended discussions that had arisen following earlier somewhat elusive ECJ-decisions. Whether this will be the last word to be heard on the topic remains to be seen.
15min to detect bacterial infections – that’s what British diagnostics company FluoretiQ Ltd is offering in the fight against antimicrobial resistance. A short interview with CEO Neciah Dorh.
Interview with Ian Harrow from the Pistoia Alliance, about how to improve life sciences data management with help of a new digital toolkit that makes data Findable, Accessible, Interoperable, and Reusable – in brief: FAIR.
An impulse paper of a green splinter group has ignited a storm in the water glass. Like industry and science lobbyists, the renegades are calling for changes to the EU’s legal GMO framework.
A challenge whose success lies in efficient process management and digital development! The times of digitalisation and Industry 4.0 do not stop at the production of medical cannabis for the pharmaceutical industry. The combination of IT systems and blockchain-based processes allows the value-added chain to be automated and the data generated to be mapped in a tamper-proof manner.
The medical cannabis market has grown significantly in recent years. In Germany, the quantity of imported cannabis products has increased dramatically. In comparison to only 1.2 tons in 2017, German medical cannabis distributors imported about 3.13 metric tons of cannabis flowers for direct medical care of patients in 2018, while around 120 kg have been re-exported. In 2019, this amount doubled to around 6.7 tons.